NASDAQ: TSHATaysha Gene Therapies Inc Stock Ownership - Who owns Taysha Gene Therapies?
Insider buying vs selling
Have Taysha Gene Therapies Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Kamran Alam | CHIEF FINANCIAL OFFICER | 2024-02-02 | 1,288 | $1.51 | $1.94kSell |
| Paul B. Manning | 10% Owner | 2023-11-17 | 100,000 | $1.63 | $163.00kBuy |
| Kamran Alam | Chief Financial Officer | 2023-08-24 | 33,000 | $2.33 | $76.89kSell |
| Sean P. Nolan | Chief Executive Officer | 2023-08-16 | 444,444 | $0.90 | $400.00kBuy |
| John A. Stalfort Iii | Director | 2023-08-16 | 388,889 | $0.90 | $350.00kBuy |
| Phillip B. Donenberg | Director | 2023-08-16 | 111,111 | $0.90 | $100.00kBuy |
| Paul B. Manning | 10% Owner | 2023-08-16 | 16,466,667 | $0.90 | $14.82MBuy |
| John A. Stalfort Iii | Director | 2023-08-16 | 388,889 | $0.90 | $350.00kBuy |
| Ra Session Ii | 10% Owner | 2023-07-13 | 5,344 | $0.70 | $3.74kSell |
| Ra Session Ii | 10% Owner | 2023-07-12 | 80,528 | $0.71 | $57.01kSell |
TSHA insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when TSHA insiders and whales buy or sell their stock.
TSHA Shareholders
What type of owners hold Taysha Gene Therapies Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Fmr LLC | 12.00% | 22,439,124 | $57.78M | Institution |
| Ra Capital Management LP | 9.88% | 18,472,503 | $47.57M | Institution |
| Rtw Investments LP | 9.03% | 16,893,185 | $43.50M | Institution |
| Vr Adviser LLC | 5.57% | 10,412,872 | $26.81M | Institution |
| Ra Session Ii | 4.82% | 9,012,837 | $23.21M | Insider |
| Audentes Therapeutics Inc | 3.89% | 7,266,342 | $18.71M | Insider |
| Paul B. Manning | 3.46% | 6,479,609 | $16.68M | Insider |
| Vanguard Group Inc | 3.31% | 6,195,567 | $15.95M | Institution |
| Avoro Capital Advisors LLC | 2.33% | 4,355,555 | $11.22M | Institution |
| Baker Bros Advisors LP | 2.14% | 4,004,756 | $10.31M | Institution |
TSHA vs Biotech Stocks
Taysha Gene Therapies Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.